重药控股：子公司药物获临床试验批准

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Chongqing Pharmaceutical Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which is intended for clinical trials [1] Group 1 - The drug Prasugrel Hydrochloride Tablets is a third-generation inhibitor of ADP-induced platelet aggregation [1] - The drug is indicated for the prevention of thrombus formation in patients with acute coronary syndrome after percutaneous coronary intervention, stable angina, and old myocardial infarction [1]